<DOC>
	<DOC>NCT00088556</DOC>
	<brief_summary>The purpose of this trial is to study the efficacy and safety of the triplet combination of TLK286, carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer.</brief_summary>
	<brief_title>Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>18 years of age or older Histologically confirmed nonsmall cell lung cancer (NSCLC) Stage IV or IIIB (disease that is not eligible for combined modality chemotherapy and radiation) Measurable disease by RECIST ECOG status of 01 Adequate liver and renal function Adequate bone marrow reserves Prior chemotherapy, immunotherapy or biologic therapy for metastatic NSCLC Up to one prior adjuvant or neoadjuvant chemotherapy is allowed History of bone marrow transplantation or stem cell support Pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
</DOC>